Pregnancy and contraception in heart disease and pulmonary arterial hypertension

Journal of Family Planning and Reproductive Health Care

Volumn 32, Issue 2, 2006, Pages 75-81

  Thorne, Sara ^a   Nelson Piercy, Catherine ^b   MacGregor, Anne ^c   Gibbs, Simon ^d   Crowhurst, John ^d   Panay, Nick ^d   Rosenthal, Eric ^b   Walker, Fiona ^e   Williams, David ^f   De Swiet, Michael ^g   Guillebaud, John ^h  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e MIDDLESEX HOSPITAL   (United Kingdom)

^f Napolitano and Prof David)   (United Kingdom)

^g QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; LEVONELLE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE;

CARDIOVASCULAR RISK; CONTRACEPTION; DOPPLER FLOWMETRY; DRUG HYPERSENSITIVITY; ECTOPIC PREGNANCY; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; INSTRUMENT STERILIZATION; INTRAUTERINE CONTRACEPTIVE DEVICE; MARFAN SYNDROME; MATERNAL MORTALITY; NAUSEA; PATIENT COMPLIANCE; PREGNANCY; PULMONARY HYPERTENSION; RATING SCALE; REVIEW; SEXUALLY TRANSMITTED DISEASE; SYSTOLIC BLOOD PRESSURE; VOMITING;

CONSENSUS; CONTRACEPTIVE AGENTS; COUNSELING; FAMILY PLANNING SERVICES; FEMALE; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; MATERNAL MORTALITY; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY, HIGH-RISK; RISK ASSESSMENT; STERILIZATION, REPRODUCTIVE;

EID: 33646001779     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118906776276486     Document Type: Review

References (21)

1. Lewis G (ed.). Why Mothers Die 2000-2002. The Sixth Report of Confidential Enquiries into Maternal Deaths in the United Kingdom. London, UK: RCOG Press, 2004.
2. Guillebaud J. Contraception Today (5th edn). London, UK: Taylor & Francis, 2003.
3. Leonard H, O'Sullivan JJ, Hunter S. Family planning requirements in the adult congenital heart disease clinic. Heart 1996; 76: 60-62.
4. Guillebaud J. Medical-eligibility criteria for contraceptive use. Lancet 2001; 357: 1378-1379.
5. World Health Organization (WHO). Medical Eligibility Criteria for Contraceptive Use (3rd edn). Geneva, Switzerland: WHO, 2004.
6. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al; Cardiac Disease in Pregnancy (CARPREG) Investigators. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104: 515-521
7. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25: 2243-2278.
8. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001; 104: 2797-2802
9. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 though 1996. J Am Coll Cardiol 1998; 31: 1650-1657.
10. Weiss BM, von Segesser LK, Alon E, Seifert B, Turina MI. Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984-1996. Am J Obstet Gynecol 1998; 179(6 Pt 1): 1643-1653.
11. Lind J, Wallenburg HC. The Marfan syndrome and pregnancy: a retrospective study in a Dutch population. Eur J Obstet Gynecol Reprod Biol 2001; 98: 28-35.
12. Elkyam U, Ostrzega E, Shotan A, Mehra A. Cardiovascular problems in pregnant women with the Marfan syndrome. Ann Intern Med 1995; 123: 117-122.
13. Presbitero P, Somerville J, Stone S, Anita E, Spiegelhalter D, Rabajoli F. Pregnancy in cyanotic congenital heart disease. Circulation 1994; 89: 2673-2676.
14. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilisation: findings from the US Collaborative Review of Sterilisation [CREST Study]. Am J Obstet Gynecol 1996; 174: 1161-1170.
15. Royal College of Obstetricians and Gynaecologists (RCOG). Male and Female Sterilisation (National Evidence-Based Clinical Guideline No. 4). London, UK: RCOG Press, 2003.
16. Kerin JF, Cooper JM, Price T, Herendael BJ, Cayuela-Font E, Cher D, et al. Hysteroscopic sterilization using a micro-insert device: results of a multicentre Phase II study. Hum Reprod 2003; 18: 1223-1230.
17. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318: 1148-1152.
18. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001; 38: 613-623.
19. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestogens alone. Lancet 1999; 354: 1610-1611.
20. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception, World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception 1998; 57: 315-324.
21. Heinemann LAJ, Assman A, DoMinh T, Garbe E and the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4: 67-73.